Literature DB >> 21465181

Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.

Muthu K Shanmugam1, Peramaiyan Rajendran, Feng Li, Tarang Nema, Shireen Vali, Taher Abbasi, Shweta Kapoor, Ashish Sharma, Alan Prem Kumar, Paul C Ho, Kam M Hui, Gautam Sethi.   

Abstract

Activation of transcription factors nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) is frequently observed in prostate cancer and has been linked with tumor cell proliferation, invasion, metastasis, and angiogenesis. In this study, we investigated the effect of ursolic acid (UA) on NF-κB and STAT3 signaling pathways in both androgen-independent (DU145) and androgen-dependent (LNCaP) prostate cancer cell lines and also prospectively tested the hypothesis of NF-κB and STAT3 inhibition using a virtual predictive functional proteomics tumor pathway technology platform. We found that UA inhibited constitutive and TNF-α-induced activation of NF-κB in DU145 and LNCaP cells in a dose-dependent manner. The suppression was mediated through the inhibition of constitutive and TNF-α-induced IκB kinase (IKK) activation, phosphorylation of IκBα and p65 and NF-κB-dependent reporter activity. Furthermore, UA suppressed both constitutive and inducible STAT3 activation in prostate cancer cells concomitant with suppression of activation of upstream kinases (Src and JAK2) and STAT3-dependent reporter gene activity. UA also downregulated the expression of various NF-κB and STAT3 regulated gene products involved in proliferation, survival, and angiogenesis and induced apoptosis in both cells lines as evidenced by DNA fragmentation and annexin V staining. In vivo, UA (200 mg/kg b.w.) treated for 6 weeks inhibited the growth of DU145 cells in nude mice without any significant effect on body weight. Overall, our results from experimental and predictive studies suggest that UA mediates its anti-tumor effects through suppression of NF-κB and STAT3 pathways in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465181     DOI: 10.1007/s00109-011-0746-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

1.  Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice.

Authors:  D D Mickey; K R Stone; H Wunderli; G H Mickey; R T Vollmer; D F Paulson
Journal:  Cancer Res       Date:  1977-11       Impact factor: 12.701

Review 2.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

Authors:  S Ghosh; M J May; E B Kopp
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

4.  Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells.

Authors:  Feng Li; Prasana Priscilla Fernandez; Peramaiyan Rajendran; Kam M Hui; Gautam Sethi
Journal:  Cancer Lett       Date:  2010-01-06       Impact factor: 8.679

Review 5.  Pharmacology of oleanolic acid and ursolic acid.

Authors:  J Liu
Journal:  J Ethnopharmacol       Date:  1995-12-01       Impact factor: 4.360

6.  Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.

Authors:  Ashutosh K Pathak; Manisha Bhutani; Asha S Nair; Kwang Seok Ahn; Arup Chakraborty; Humam Kadara; Sushovan Guha; Gautam Sethi; Bharat B Aggarwal
Journal:  Mol Cancer Res       Date:  2007-09       Impact factor: 5.852

Review 7.  Prostate cancer.

Authors:  Jan-Erik Damber; Gunnar Aus
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 9.  TNF: a master switch for inflammation to cancer.

Authors:  Gautam Sethi; Bokyung Sung; Bharat B Aggarwal
Journal:  Front Biosci       Date:  2008-05-01

Review 10.  Nuclear factor-kappa B: from clone to clinic.

Authors:  Kwang Seok Ahn; Gautam Sethi; Bharat B Aggarwal
Journal:  Curr Mol Med       Date:  2007-11       Impact factor: 2.222

View more
  48 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 2.  Therapeutic modulators of STAT signalling for human diseases.

Authors:  Gabriella Miklossy; Tyvette S Hilliard; James Turkson
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

3.  Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer.

Authors:  Lalitha Ramachandran; Kanjoormana Aryan Manu; Muthu K Shanmugam; Feng Li; Kodappully Sivaraman Siveen; Shireen Vali; Shweta Kapoor; Taher Abbasi; Rohit Surana; Duane T Smoot; Hassan Ashktorab; Patrick Tan; Kwang Seok Ahn; Chun Wei Yap; Alan Prem Kumar; Gautam Sethi
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

4.  Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.

Authors:  Kaiyong Yang; Yan Chen; Jiaqian Zhou; Lin Ma; Yating Shan; Xiaoying Cheng; Yun Wang; Zhaoxin Zhang; Xiaojun Ji; Lili Chen; Hui Dai; Biqing Zhu; Chen Li; Zhonghua Tao; Xichun Hu; Wu Yin
Journal:  Br J Pharmacol       Date:  2019-12-26       Impact factor: 8.739

5.  Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.

Authors:  Yulin Ren; Gerardo D Anaya-Eugenio; Austin A Czarnecki; Tran Ngoc Ninh; Chunhua Yuan; Hee-Byung Chai; Djaja D Soejarto; Joanna E Burdette; Esperanza J Carcache de Blanco; A Douglas Kinghorn
Journal:  Bioorg Med Chem       Date:  2018-07-17       Impact factor: 3.641

Review 6.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 7.  Cancer prevention with promising natural products: mechanisms of action and molecular targets.

Authors:  Poyil Pratheeshkumar; Chakkenchath Sreekala; Zhuo Zhang; Amit Budhraja; Songze Ding; Young-Ok Son; Xin Wang; Andrew Hitron; Kim Hyun-Jung; Lei Wang; Jeong-Chae Lee; Xianglin Shi
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

8.  Side chain-functionalized aniline-derived ursolic acid derivatives as multidrug resistance reversers that block the nuclear factor-kappa B (NF-κB) pathway and cell proliferation.

Authors:  Ri-Zhen Huang; Shi-Xian Hua; Zhi-Xin Liao; Xiao-Chao Huang; Heng-Shan Wang
Journal:  Medchemcomm       Date:  2017-05-12       Impact factor: 3.597

9.  Synthesis and discovery of asiatic acid based 1,2,3-triazole derivatives as antitumor agents blocking NF-κB activation and cell migration.

Authors:  Ri-Zhen Huang; Gui-Bin Liang; Mei-Shan Li; Yi-Lin Fang; Shi-Feng Zhao; Mei-Mei Zhou; Zhi-Xin Liao; Jing Sun; Heng-Shan Wang
Journal:  Medchemcomm       Date:  2019-03-01       Impact factor: 3.597

Review 10.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.